Photos of searchers seeking victims of a Hiroshima bombing 80 years later on a nearby island
Because of poor medicine and care, only a few hundred were alive when the field hospital closed Aug. 25, according to historical records. They were buried in various locations in chaotic and rushed operations.
Decades later, people in the area are looking for the remains of the missing, driven by a desire to account for and honor the victims and bring relief to survivors who are still tormented by memories of missing loved ones.
Rebun Kayo, a Hiroshima University researcher, regularly visits Ninoshima to search for remains.
This is a photo gallery curated by AP photo editors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
When does the body really start aging? The answer may surprise you.
When does aging really shift into overdrive? A new study suggests it may be sooner than you think. Scientists at the Chinese Academy of Sciences studied proteins in tissue taken from about 70 people ages 14 to 68, according to the study published July 25 in the journal Cell. These proteins give scientists a window of when the aging process may begin on a cellular level, said Dr. Thomas Blackwell, associate dean for graduate medical education and professor of medicine at the University of Texas Medical Branch. Proteins are created in a 'factory' using instructions from messenger RNA, he said. A sign of aging is when the cells' ability to make proteins correctly and efficiently starts to break down. By looking at tissues taken from organs throughout the body, including the heart, liver, pancreas, spleen, lung, skin and muscles, researchers determined that aging starts to accelerate from 45 to 55. They also found that organs aged at different rates. For example, the spleen, aorta (the body's main artery) and adrenal gland (responsible for producing hormones) showed signs of aging at around 30. The aorta also saw the biggest changes in protein levels around the ages of 45 and 55. 'This is just a beautiful roadmap that gives us an initial overview of organ aging,' said Neville Sanjana, associate professor of biology, neuroscience and physiology at New York University and a faculty member at the New York Genome Center. The study's findings could have a lot of implications in future research into treatments for chronic conditions related to aging that would not only add decades to patients' lifespan, but also their health span, which is the period of a person's life spent in good health, he said. 'To me, that's exciting,' Sanjana said. 'This kind of data generation is so powerful for folks who want to do things like bioengineering and creating new kinds of therapies to restore healthy aging.' For Blackwell, the study also shows that patients still have the chance to change their aging trajectory later in life – 'but the window is short,' he said. The best ways to add healthy years to your life are to maintain a healthy level of blood pressure, blood sugar and cholesterol, don't smoke and drink "very little," Blackwell said. Research has shown diet, exercise, genetics and, sometimes, luck, impact longevity. However, the new study suggests people may still see benefits from changes later in life. 'Starting at 45 to 50, you could gain as much as 10 years of healthy life and this study just shows the truth of that at a cellular level,' he said. Adrianna Rodriguez can be reached at adrodriguez@ This article originally appeared on USA TODAY: Aging: Body starts changing after 50. Here's what happens. Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
Brazil, Japan beef talks focus on smaller Brazilian states, upsetting industry
By Ana Mano and Marcela Ayres SAO PAULO (Reuters) -Ongoing talks to open the Japanese market to Brazilian beef are focusing on supplies from three small Brazilian exporting states, upsetting other parts of the South American country's industry that are eager to reach the high-paying customers, according to multiple sources. Brazil, the world's biggest beef exporter, has tried for two decades to crack the Japanese market without success. A deal would give Japan an alternative to its top suppliers, the United States and Australia, at a time when U.S. tariffs are reshaping global food trade. Negotiations gained momentum after a state visit of Brazil's President Luiz Inacio Lula da Silva in March to Japan, one of the world's largest beef importers. But the current state of talks, which focus on states representing less than 4% of Brazil's exports by volume, worries meatpackers in the big beef-producing states of Sao Paulo, Mato Grosso, Mato Grosso do Sul, and Para. Together, they accounted for nearly 60% of Brazil's total beef exports, or 1.72 million metric tons last year. A Brazilian government memo, issued after a technical visit by Japanese officials in June, showed Brasília answered "a questionnaire for the import of beef from the southern part of the Republic Federation of Brazil," naming Rio Grande do Sul, Parana, and Santa Catarina. Those three small exporting states were declared free of foot-and-mouth, a contagious viral disease in cattle, earlier than the other states, although Brazil acquired in May the national status of being free of the disease without vaccination from the World Organization for Animal Health. Brazil's last outbreak of the disease was in 2006, according to the government. The Brazilian Agriculture Ministry did not have an immediate comment on its talks with Japan. A local government source, who asked not to be named, confirmed talks were taking place by region. The person said Brazil initially has no plans to negotiate permits beyond the three states. Beef sector representatives, including exporters, told Reuters they hope more states will be included. "We know talks are difficult," said Paulo Mustefaga, head of beef lobbying group Abrafrigo, which represents Marfrig and smaller beef exporters. "The surprise for us is that this is now moving towards approval for only three states." Japan's Ministry of Agriculture, Forestry and Fisheries said it was aware of Brazil's status of being free of foot-and-mouth disease. It added that Japan is "conducting a risk assessment in accordance with Japanese procedures" ahead of issuing any export permits to Brazilian meatpackers, without elaborating. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio's DEX-G2 Blood Test For Early Detection of Gastric Cancer
SAN ANTONIO, Aug. 5, 2025 /PRNewswire/ -- A groundbreaking multicenter clinical study published on July 30 in JAMA Surgery confirms the powerful diagnostic performance of the Destinex assay, a novel liquid biopsy that serves as the foundation for Cizzle Bio's DEX-G2 blood-based assay for early detection of gastric cancer—one of the world's deadliest malignancies. The study's findings validate the clinical utility of DEX-G2 as a minimally invasive, clinically actionable tool to detect gastric cancer at its earliest and most treatable stages, when timely intervention can significantly improve outcomes and save lives. The DESTINEX study, conducted at leading cancer centers in Japan and South Korea, evaluated a signature panel of microRNAs derived from exosomes and cell-free serum. The study analyzed 809 serum specimens from 480 participants, including patients with gastric cancer and matched controls. Using machine learning to refine and validate the assay, researchers demonstrated exceptional diagnostic accuracy for early-stage gastric cancer. The study was led by Ajay Goel, Ph.D., AGAF, an internationally recognized leader in cancer biomarker research and the developer of the Destinex assay. Goel also serves as scientific advisor to Cizzle Bio and is chair of the Department of Diagnostics and Experimental Therapeutics at City of Hope Comprehensive Cancer Center, where he led the development of the Destinex assay into the DEX-G2 blood test that Cizzle Bio is now advancing for near-term commercial launch. "The publication of this study in JAMA Surgery is a critical milestone, not only for our scientific team but also for the future of early gastric cancer detection," said Goel. "By combining the sensitivity of cell-free microRNAs with the specificity of exosomal markers, Destinex—and now DEX-G2—offers a minimally invasive, accessible, and highly accurate method for detecting gastric cancer at a stage when outcomes can be dramatically improved." In the study, the Destinex assay achieved an area under the curve (AUC) of 96.8% in the validation cohort, with a sensitivity of 95.0% for detecting early-stage (pT1) gastric cancer. These findings underscore the assay's strength as a minimally invasive tool for identifying gastric cancer early when it is most curable. The assay achieved high sensitivity and specificity in distinguishing individuals with gastric cancer from those without the disease, confirming its potential not only as a minimally invasive screening tool but also to significantly improve patient outcomes through earlier detection and intervention. A Pressing Clinical Need Gastric cancer is the third leading cause of cancer-related deaths worldwide, mainly due to delayed diagnosis. Globally, more than 60% of gastric cancer cases are diagnosed at advanced stages, when curative treatment is no longer an option and prognosis is poor. Endoscopic screening has helped reduce mortality in high-incidence countries such as Japan and Korea, but its cost, invasiveness, and limited availability make it impractical for widespread use in low-incidence regions. Minimally invasive blood-based tests like DEX-G2 have the potential to fill this gap. The Destinex assay, the scientific basis of DEX-G2, demonstrated outstanding sensitivity and specificity for detecting early-stage (T1) gastric cancer, and its diagnostic performance remained robust across tumor stages and patient subgroups. The study also showed a significant drop in biomarker levels after surgical tumor removal, confirming the assay's tumor specificity. Read the full JAMA Surgery study here: "This study reinforces the scientific credibility and clinical utility of the technology behind DEX-G2," said Bill Behnke, CEO of Cizzle Bio. "We are proud to advance this innovation into clinical practice, where it has the potential to make earlier detection a reality for patients who currently have few options for early detection." From Discovery to Clinical Application Cizzle Bio is advancing its DEX-G2 test, based on the Destinex assay, for near-term commercial deployment in CLIA-certified laboratories. It is intended to support clinicians in detecting gastric cancer earlier, particularly in primary care and gastroenterology settings where endoscopy may not be accessible or practical. The company holds a worldwide exclusive license for DEX-G2 and is actively pursuing commercialization in both U.S. and global markets, with a focus on reaching populations where gastric cancer is often diagnosed too late for curative treatment. About Cizzle Bio Cizzle Bio is a Texas-based biotechnology company dedicated to revolutionizing cancer diagnostics by advancing biomarker-based blood tests, starting with early detection of lung and gastric cancers. Our goal is to empower patients, equip clinicians, and improve outcomes through innovation, compassion, and life-saving solutions. We hold exclusive licensing rights for our groundbreaking CIZ1B biomarker test in the United States, Canada, and the Caribbean and a worldwide exclusive license for our DEX-G2 biomarker gastric cancer test. Cizzle Bio is commercializing both tests for U.S. clinical Media Contact: Yolanda Heibergeryolanda@ View original content to download multimedia: SOURCE Cizzle Bio
